Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | MMP8 | P22894 | 3/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27742525 | 0.96 | LMNA (0.59) | LMNATSHRCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4779824 | 0.96 | LMNA (0.59) | LMNATSHRCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4780592 | 0.87 | CYP2D6 (0.55) | LMNACYP2D6CYP2C9CYP2C19KMT2A | |
| SCHEMBL4780368 | 0.83 | KMT2A (0.53) | LMNACYP2D6CYP2C9CYP2C19KMT2A | |
| SCHEMBL7447243 | 0.80 | ATM (0.54) | LMNATSHRCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL3782668 | 0.77 | ATM (0.56) | LMNATSHRCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL3782666 | 0.77 | ATM (0.56) | LMNATSHRCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL11873362 | 0.75 | KDM4A (0.62) | CYP2D6CYP2C9CYP2C19KMT2AMMP8 | |
| SCHEMBL9829299 | 0.75 | LMNA (0.77) | LMNATSHRKMT2AHDAC3MAPK1 | |
| SCHEMBL25092652 | 0.75 | CYP2D6 (0.53) | LMNATSHRCYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080319065-A1 | Systemic and Intrathecal Effects of a Novel Series of Phospholipase A2 Inhibitors on Hyperalgesia and Spinal Pge2 Release | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-12-25 | — | — | US | disclosed |
| CN-101291666-A | Systemic and intrathecal effects of a novel series of phospholipase a2 inhibitors on hyperalgesia and spinal pge2 release | UNIV CALIFORNIA (US) | 2008-10-22 | — | — | CN | disclosed |
| EP-1937247-A2 | SYSTEMIC AND INTRATHECAL EFFECTS OF A NOVEL SERIES OF PHOSPHOLIPASE A2 INHIBITORS ON HYPERALGESIA AND SPINAL PGE2 RELEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007022443-A2 | SYSTEMIC AND INTRATHECAL EFFECTS OF A NOVEL SERIES OF PHOSPHOLIPASE A2 INHIBITORS ON HYPERALGESIA AND SPINAL PGE2 RELEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319065-A1 | Systemic and Intrathecal Effects of a Novel Series of Phospholipase A2 Inhibitors on Hyperalgesia and Spinal Pge2 Release | PLA2G4A, PLA2G4B, PLA2G2A | LMNA 2391/4885TSHR 4228/4885CYP2D6 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.